eMedicine Specialties > Ophthalmology > Intraocular Pressure

Posner-Schlossman Syndrome

Author: James H Oakman Jr, MD, Partner, Southern Eye Center, Augusta, Georgia
Contributor Information and Disclosures

Updated: Nov 6, 2008

Introduction

Background

Glaucomatocyclitic crisis is a condition with self-limited recurrent episodes of markedly elevated intraocular pressure (IOP) with mild idiopathic anterior chamber inflammation. It is most often classified as secondary inflammatory glaucoma.

In 1948, Posner and Schlossman first recognized glaucomatocyclitic crisis and described the features of this syndrome.1 For this reason, the entity is often termed Posner-Schlossman syndrome (PSS).

Posner and Schlossman identified the following features2 :

  • Recurrent episodes of mild cyclitis
  • Uniocular involvement
  • Duration of attack varying from a few hours to several weeks
  • Signs of a slight decrease in vision, elevated IOP with open angles, corneal edema with a few keratic precipitates, heterochromia with anisocoria, and a large pupil in the affected eye
  • Normal visual fields
  • Normal optic disc
  • Normal IOP, outflow facility, and all provocative tests between episodes

Since this original description, other cases attributed to glaucomatocyclitic crisis have been found to deviate from these criteria.3 For instance, some patients with glaucomatocyclitic crisis have abnormal aqueous humor dynamics and may have an underlying primary open-angle glaucoma (POAG).4

Additional features that are now recognized are as follows:

  • Almost exclusively, this condition affects individuals aged 20-50 years.
  • Both eyes may be involved at different times but very rarely contemporaneously.5,6
  • The rise of IOP is out of proportion to the severity of the uveitis, and this rise in IOP precedes the identifiable inflammatory reaction, often by several days.

Pathophysiology

Episodic changes in the trabecular meshwork lead to impairment of outflow facility and result in an elevation of IOP. These changes are accompanied by mild intraocular inflammation. In the acute phase of PSS, optic nerve head parameters and retinal flow rates were altered; however, all returned to normal without any permanent damage after resolution of the elevated IOP. Electroretinogram studies in the acute phase demonstrate a selective reduction in the S-cone b-wave.7

Frequency

United States

Glaucomatocyclitic crisis is a rare condition.

International

In Finland, the incidence is 0.4 and the prevalence is 1.9 per 100,000 population.8

Mortality/Morbidity

Prolonged IOP elevation results in damage to the optic nerve head and visual field defects.9

Age

This condition almost exclusively affects individuals aged 20-50 years. Rarely, episodes occur in individuals older than 60 years. Also, rarely, episodes have been reported in adolescence.10

Clinical

History

  • In general, the symptomatology is vague.
  • Most commonly, a crisis presents with slight discomfort. The patient may be pain-free even though the IOP is quite elevated.
  • The patient may report blurred vision or halo vision if the IOP is high and induces corneal edema.
  • A history of past attacks of blurred vision lasting several days, which recurs monthly or yearly, is usual.
  • Each crisis may last several hours to a few weeks.
  • Patients follow a variable clinical course; some experience 1 or 2 episodes in their lives, while others have recurrences over many years.
  • Typically, these episodes decrease in frequency with advancing age.

Physical

  • On examination, the eye is quiet with either no injection or a mild ciliary flush.
  • The pupil often is dilated slightly or sluggishly reactive; the anterior chamber is deep and has an open angle.
  • This condition should be differentiated from closed-angle glaucoma with the help of gonioscopy.
  • IOP usually is elevated in the range of 40-60 mm Hg.
  • IOP is related to the duration of uveitis but not to the degree of uveitis.
  • Eyes with active inflammatory disease often have wide swings in IOP, leading to glaucomatous damage.
  • The elevated IOP can last for several hours to a few weeks; therefore, it can be missed on initial examination.
  • If the elevated IOP is of significant duration and elevation, corneal epithelial edema develops.
  • Signs of anterior inflammation are characteristically minimal with faint flare, rare cells, and only a few keratic precipitates that are stellate, flat, nonpigmented, and concentrated over the inferior half of the endothelium.11
  • Fine keratic precipitates appear after 2-3 days of elevated IOP and resolve rapidly.
  • The inflammation never leads to the development of posterior synechiae or peripheral anterior synechiae.
  • Fresh precipitates may appear with each episode of increased IOP.
  • Heterochromia, described originally, is no longer considered a characteristic of this syndrome.
  • Typical of inflammatory conditions, early segmental iris ischemia and associated late iris-vessel congestion have been observed. These vessels leak on iris fluorescein angiography.

Causes

  • The etiology of glaucomatocyclitic crisis has remained elusive. Several factors have been postulated as contributors to the development of glaucomatocyclitic crisis, to include the following:
    • Abnormal vascular process
    • Autonomic defect
    • Allergic condition
    • Variation of developmental glaucoma
    • Cytomegalovirus (CMV)12,13
    • Herpes simplex virus14
  • Description of a final common pathway usually includes a reference to changes in the trabecular meshwork leading to a reduction of outflow facility. However, some authors describe an increase in aqueous production.
  • Transfer coefficients of fluorescein in aqueous in the anterior chamber, by flow and by diffusion, are elevated during attacks of glaucomatocyclitic crisis. Between attacks, both coefficients return to normal.15
  • Elevations in IOP are postulated to be secondary to inflammation of the trabecular meshwork, which may be mediated by prostaglandins.
  • Prostaglandins, especially prostaglandin E, have been found in higher concentration in the aqueous humor of patients during acute attacks. These levels return to normal between episodes.16,17
    • In a study using rabbit eyes, prostaglandin E was shown to contribute to a breakdown of the blood-aqueous barrier. This increase in the transfer coefficient of fluorescein is consistent with a similar response in animal eyes to prostaglandin E.
    • The vascular effects of prostaglandins may contribute to the tortuosity seen in iris vessels and the leakage demonstrated with fluorescein angiography of the iris.
    • To confuse matters, in another animal study, elevated prostaglandins increased outflow facility, which would contribute to a lower IOP and, thus, not be consistent with the reduced outflow facility seen in patients with glaucomatocyclitic crisis during an acute episode.18
    • Another theory purports an increased aqueous production resulting from elevated levels of aqueous prostaglandins.
    • In summary, the exact mechanism by which prostaglandins regulate IOP has not been described, but a direct correlation between elevated levels of prostaglandins in the aqueous humor and the level of IOP has been found during acute attacks of glaucomatocyclitic crisis.
  • Evidence exists that glaucomatocyclitic crisis may be associated with POAG. Patients with a 10-year or longer history of PSS are 3 times more likely to develop visual field changes and optic disc changes.19 These patients may have a higher than normal incidence of corticosteroid responsiveness, leading to an elevated IOP. This must be kept in mind during the treatment of this disorder with corticosteroids.
  • Associations with immunogenetic factors also exist; in one study, the presence of human leukocyte antigen Bw54 (HLA-Bw54) was found in 41% of patients.20
  • Associations with certain allergic conditions and gastrointestinal diseases, most notably peptic ulcer disease, have been described.21

More on Posner-Schlossman Syndrome

Overview: Posner-Schlossman Syndrome
Differential Diagnoses & Workup: Posner-Schlossman Syndrome
Treatment & Medication: Posner-Schlossman Syndrome
Follow-up: Posner-Schlossman Syndrome
References

References

  1. Posner A, Schlossman A. Syndrome of unilateral recurrent attacks of glaucoma with cyclitic symptoms. Arch Ophthalmol. 1948;39:517.

  2. Posner A, Schlossman A. Further observations on the syndrome of glaucomatocyclitic crisis. Trans Am Acad Ophthalmol Otolaryngol. 1953;57:531.

  3. Theodore FH. Observations on glaucomatocyclitic crisis. Br J Ophthalmol. 1952;36:207.

  4. Kass MA, Becker B, Kolker AE. Glaucomatocyclitic crisis and primary open-angle glaucoma. Am J Ophthalmol. Apr 1973;75(4):668-73. [Medline].

  5. Levatin P. Glaucomatocyclitic crisis occurring in both eyes. Am J Ophthalmol. 1956;41:1056.

  6. Dinakaran S, Kayarkar V. Trabeculectomy in the management of Posner-Schlossman syndrome. Ophthalmic Surg Lasers. Jul-Aug 2002;33(4):321-2. [Medline].

  7. Maeda H, Nakamura M, Negi A. Selective reduction of the S-cone component of the electroretinogram in Posner-Schlossman syndrome. Eye. Apr 2001;15:163-7. [Medline].

  8. Päivönsalo-Hietanen T, Tuominen J, Vaahtoranta-Lehtonen H, et al. Incidence and prevalence of different uveitis entities in Finland. Acta Ophthalmol Scand. Feb 1997;75(1):76-81. [Medline].

  9. Darchuk V, Sampaolesi J, Mato L, et al. Optic nerve head behavior in Posner-Schlossman syndrome. Int Ophthalmol. 2001;23(4-6):373-9. [Medline].

  10. Burnstein Y, Shelton K, Higginbotham EJ. Glaucomatocyclitic crisis in a child. Am J Ophthalmol. Jul 1998;126(1):136-7. [Medline].

  11. Pillai CT, Dua HS, Azuara-Blanco A, et al. Evaluation of corneal endothelium and keratic precipitates by specular microscopy in anterior uveitis. Br J Ophthalmol. Dec 2000;84(12):1367-71. [Medline].

  12. Bloch-Michel E, Dussaix E, Cerqueti P, et al. Possible role of cytomegalovirus infection in the etiology of the Posner-Schlossmann syndrome. Int Ophthalmol. Dec 1987;11(2):95-6. [Medline].

  13. Teoh SB, Thean L, Koay E. Cytomegalovirus in aetiology of Posner-Schlossman syndrome: evidence from quantitative polymerase chain reaction. Eye. Dec 2005;19(12):1338-40. [Medline].

  14. Yamamoto S, Pavan-Langston D, Tada R, et al. Possible role of herpes simplex virus in the origin of Posner-Schlossman syndrome. Am J Ophthalmol. Jun 1995;119(6):796-8. [Medline].

  15. Nagataki S, Mishima J. Aqueous humor dynamics in glaucomatocyclitic crisis. Invest Ophthalmol. 1976;15:365.

  16. Masuda K, Izawa Y, Mishima S. Prostaglandins and glaucomatocyclitic crisis. Jpn J Ophthalmol. 1975;19:368.

  17. Neufeld AH, Sears ML. Prostaglandin and eye. Prostaglandins. Aug 1973;4(2):157-75. [Medline].

  18. Eakins KE. Increased intraocular pressure produced by prostaglandins E1 and E2 in the cat eye. Exp Eye Res. Jul 1970;10(1):87-92. [Medline].

  19. Jap A, Sivakumar M, Chee SP. Is Posner Schlossman syndrome benign?. Ophthalmology. May 2001;108(5):913-8. [Medline].

  20. Hirose S, Ohno S, Matsuda H. HLA-Bw54 and glaucomatocyclitic crisis. Arch Ophthalmol. Dec 1985;103(12):1837-9. [Medline].

  21. Knox DL. Glaucomatocyclitic crises and systemic disease: peptic ulcer, other gastrointestinal disorders, allergy and stress. Trans Am Ophthalmol Soc. 1988;86:473-95. [Medline].

  22. Kim R, Van Stavern G, Juzych M. Nonarteritic anterior ischemic optic neuropathy associated with acute glaucoma secondary to Posner-Schlossman syndrome. Arch Ophthalmol. Jan 2003;121(1):127-8. [Medline].

  23. Irak I, Katz BJ, Zabriskie NA, et al. Posner-Schlossman syndrome and nonarteritic anterior ischemic optic neuropathy. J Neuroophthalmol. Dec 2003;23(4):264-7. [Medline].

  24. Hung PT, Chang JM. Treatment of glaucomatocyclitic crises. Am J Ophthalmol. Feb 1974;77(2):169-72. [Medline].

  25. Varma R, Katz LJ, Spaeth GL. Surgical treatment of acute glaucomatocyclitic crisis in a patient with primary open-angle glaucoma. Am J Ophthalmol. Jan 15 1988;105(1):99-100. [Medline].

  26. Wong PC, Ruderman JM, Krupin T, et al. 5-Fluorouracil after primary combined filtration surgery. Am J Ophthalmol. Feb 15 1994;117(2):149-54. [Medline].

  27. Albert DM, Jakobiec FA. Principles and Practice of Ophthalmology. Vol 3. Philadelphia: Saunders; 1994:1426-35.

  28. de Roetth A Jr. Glaucomatocyclitic crisis. Am J Ophthalmol. Mar 1970;69(3):370-1. [Medline].

  29. Fiore PM. Inflammatory glaucoma. In: Albert DM, Jakobiec FA, eds. Principles and Practice of Ophthalmology. Vol 3. 1994:1426-35.

  30. Grant WM. Clinical measurements of aqueous outflow. Arch Ophthalmol. 1951;46:113.

  31. Hahn IH, Stillman MC. A case of glaucomatocyclitic crisis in the emergency department. Ann Emerg Med. Feb 2006;47(2):167-9. [Medline].

  32. Harstad HK, Ringvold A. Glaucomatocyclitic crises (Posner-Schlossman syndrome). A case report. Acta Ophthalmol (Copenh). Apr 1986;64(2):146-51. [Medline].

  33. Hart CT, Weatherill JR. Gonioscopy and tonography in glaucomatocyclitic crises. Br J Ophthalmol. Sep 1968;52(9):682-7. [Medline].

  34. Hollowich F. Clinical aspects and therapy of the Posner-Schlossman syndrome. Klin Monatsbl Augenheilkd. 1978;172:336.

  35. Hoskins HD, Kass MA. Secondary open-angle glaucoma. Diagnosis and therapy of the glaucomas. 1989;332-4.

  36. Krupin T, Feitl ME. Glaucoma associated with uveitis. In: The Glaucomas. 1989:1205-23.

  37. Perdviel G, Raynaud G, Gayard M. Syndrome de Posner-Schlossman et glaucoma. Bull Soc Ophthalmol Fr. 1962;62:611.

  38. Raitta C, Klemetti A. Steroidbelastung bei Posner-Schlossmanschem Syndrom. V Graefes Arch Klin Exp Ophthalmol. 1967;174:66. [Medline].

  39. Rhee DJ, Rapuano CJ, Belzer TL, et al. Physician Desk Reference for Ophthalmic Medicines. 2006.

  40. Riatta C, Vannas A. Glaucomatocyclitic crisis. Arch Ophthalmol. 1977;95:608.

  41. Richardson K. Acute glaucoma after trauma. In: Freeman HM, ed. Ocular Trauma. New York: Appleton-Century-Crofts; 1979.

  42. Ritch R, Shields MB, Krupin T. The Glaucomas. St. Louis: Mosby; 1989:1205-23.

  43. Shields MB. Glaucomas associated with ocular inflammation. In: Textbook of Glaucoma. 1992:356-61.

  44. Spivey BE, Armaly MF. Tonographic findings in glaucomatocyclitic crisis. Am J Ophthalmol. 1963;55:47.

Further Reading

Keywords

Posner-Schlossman syndrome, PSS, glaucomatocyclitic crisis, secondary inflammatory glaucoma, idiopathic anterior chamber inflammation, mild intraocular inflammation, intraocular pressure, IOP

Contributor Information and Disclosures

Author

James H Oakman Jr, MD, Partner, Southern Eye Center, Augusta, Georgia
James H Oakman Jr, MD is a member of the following medical societies: American Academy of Ophthalmology, American Society of Cataract and Refractive Surgery, Georgia Medical Society, Georgia Society of General Surgeons, and Georgia Society of Ophthalmology
Disclosure: Nothing to disclose.

Medical Editor

Andrew I Rabinowitz, MD, Consulting Staff, Department of Ophthalmology, Barnet Dulaney Perkins Eye Center
Andrew I Rabinowitz, MD is a member of the following medical societies: Aerospace Medical Association, American Academy of Ophthalmology, and American Medical Association
Disclosure: Nothing to disclose.

Pharmacy Editor

Simon K Law, MD, PharmD, Assistant Professor of Ophthalmology, Jules Stein Eye Institute; Chief of Section of Ophthalmology Surgical Services, Department of Veterans Affairs Healthcare Center, West Los Angeles
Simon K Law, MD, PharmD is a member of the following medical societies: American Academy of Ophthalmology, American Glaucoma Society, and Association for Research in Vision and Ophthalmology
Disclosure: Nothing to disclose.

Managing Editor

Martin B Wax, MD, Clinical Professor, Department of Ophthalmology, University of Texas Southwestern Medical School; Vice President, Ophthalmology Research and Development, Head, Ophthalmology Discovery Research, Alcon Labs, Inc
Martin B Wax, MD is a member of the following medical societies: American Academy of Ophthalmology, American Glaucoma Society, and Society for Neuroscience
Disclosure: Alcon Labs Salary Employment

CME Editor

Lance L Brown, OD, MD, Ophthalmologist, Affiliated With Freeman Hospital and St John's Hospital, Regional Eye Center, Joplin, Missouri
Disclosure: Nothing to disclose.

Chief Editor

Hampton Roy Sr, MD, Associate Clinical Professor, Department of Ophthalmology, University of Arkansas for Medical Sciences
Hampton Roy Sr, MD is a member of the following medical societies: American Academy of Ophthalmology, American College of Surgeons, and Pan-American Association of Ophthalmology
Disclosure: Nothing to disclose.

RELATED EMEDICINE ARTICLES
 
 
HONcode

We subscribe to the
HONcode principles of the
Health On the Net Foundation

All material on this website is protected by copyright, Copyright© 1994- by Medscape.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.